2-(三氟甲氧基)苯甲酸甲酯 | 148437-99-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(三氟甲氧基)苯甲酸甲酯
• 中文别名: 甲基2-(三氟甲氧基)苯甲酸盐；邻三氟甲氧基苯甲酸甲酯
• 英文名称: methyl 2-(trifluoromethoxy)benzoate
• CAS: 148437-99-4
• 化学式: C₉H₇F₃O₃
• 分子量: 220.148
• InChiKey: VDJYJSUDISVNRS-UHFFFAOYSA-N

物化性质

• 沸点：
  57 °C
• 密度：
  1.312±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2918990090
• 危险类别：
  IRRITANT
• 安全说明：
  S26,S36
• 储存条件：
  室温

SDS

Name:	Methyl 2-(trifluoromethoxy)benzoate 97% Material Safety Data Sheet
Synonym:
CAS:	148437-99-4

Section 1 - Chemical Product MSDS Name:Methyl 2-(trifluoromethoxy)benzoate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
148437-99-4	Methyl 2-(trifluoromethoxy)benzoate	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 148437-99-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 91 - 93 deg C @15mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7F3O3
Molecular Weight: 220

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Bases, oxidizing agents, reducing agents, acids.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide, acrid smoke and fumes, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 148437-99-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 2-(trifluoromethoxy)benzoate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
Shipping Name: CORROSIVE LIQUID, N.O.S.
Hazard Class: 8
UN Number: 1760
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 148437-99-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 148437-99-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 148437-99-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(三氟甲氧基)苯甲酸甲酯 在 lithium aluminium tetrahydride 、 硫酸 、 palladium on activated charcoal 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 22.25h， 生成 (5-amino-2-trifluoromethoxyphenyl)methanol
  参考文献：
  名称：

  [EN] ANTIDIABETIC COMPOUNDS AND COMPOSITIONS
  [FR] COMPOSÉS ET COMPOSITIONS ANTIDIABÉTIQUES

  摘要：

  本文提供了新颖的化合物（例如，公式I），药物组合物和与GPR40相关的使用方法。这些化合物通常是GPR40激动剂，可用于治疗各种疾病、疾病或疾病，如2型糖尿病。

  公开号：

  WO2022028317A1
• 作为产物：
  描述：

  甲醇 、 2-三氟甲氧基苯甲酸 在 硫酸 作用下， 生成 2-(三氟甲氧基)苯甲酸甲酯
  参考文献：
  名称：

  Synthesis and Selective Anticancer Activity Evaluation of 2-phenylacrylonitrile Derivatives as Tubulin Inhibitors

  摘要：

  研究目的 本研究旨在用 2-苯基丙烯腈合成 13 个系列的新型衍生物，评估它们在体内和体外的抗肿瘤活性。 与 2-苯基丙烯腈合成 13 个系列的新型衍生物，评估其体内和体外抗肿瘤活性，并获得新型微管蛋白抑制剂。 获得新型微管蛋白抑制剂。 研究方法 通过 Knoevenagel 缩合法合成了 13 个系列的 2-苯基丙烯腈衍生物，并在体内和体外评估了它们的抗肿瘤活性。 缩合合成了 13 个系列的 2-苯基丙烯腈衍生物，并用 MTT 法测定了它们的抗增殖活性。 用流式细胞仪分析细胞周期和细胞凋亡。定量细胞迁移 用 24 孔 Boyden 室进行。蛋白质通过 用 ELISA 试剂盒检测微管组装的体外动力学。 试剂盒检测微管组装的体外动力学。分子对接由 Discovery Studio (DS) 2017 客户端在线工具完成。 结果 在这些衍生物中，化合物 1g2a 对 HCT116 和 BEL-7402 具有很强的抑制活性。 对HCT116（IC50 = 5.9 nM）和BEL-7402（IC50 = 7.8 nM）细胞具有很强的抑制活性。化合物 1g2a 的选择性抗增殖活性和特异性均优于包括紫杉醇在内的所有阳性对照药物。 包括紫杉醇在内的所有阳性对照药物相比，化合物 1g2a 表现出更好的选择性抗增殖活性和特异性。化合物 1g2a 可抑制 HCT116 和 BEL-7402 细胞的增殖，使其停滞在细胞周期的 G2/M 期，抑制 HCT116 和 BEL-7402 细胞的迁移。 抑制 HCT116 和 BEL-7402 细胞的迁移以及细胞集落的形成。化合物 1g2a 对 HCT116 和 BEL-7402 细胞表现出卓越的微管蛋白聚合抑制活性。 BEL-7402 细胞表现出优异的小管蛋白聚合抑制活性。分子对接分析结果表明，1g2a 可抑制微管蛋白，从而发挥抗癌作用。 小管蛋白，从而发挥抗癌作用。 结论 化合物 1g2a 在体内和体外都显示出了突出的抗肿瘤活性，有望进一步开发成高效的抗肿瘤药物。 有可能被进一步开发成对正常组织毒性小的高效抗肿瘤药。 对正常组织毒性小的高效抗肿瘤药物。

  DOI：

  10.2174/0109298673263854231009063053

文献信息

• Identification of new aryl hydrocarbon receptor (AhR) antagonists using a zebrafish model
  作者：Jieun Jeong、Kun-Hee Kim、Dong-Young Kim、Gopalakrishnan Chandrasekaran、Minhee Kim、Suvarna H. Pagire、Mahesh Dighe、Eun Young Choi、Su-Min Bak、Eun-Young Kim、Myung-Geun Shin、Seok-Yong Choi、Jin Hee Ahn

  DOI：10.1016/j.bmc.2019.07.030

  日期：2019.10

  heterocyclic and α,β-unsaturated derivatives were synthesized and evaluated for their AhR antagonist activity using zebrafish and mammalian cells. Compounds 1b, 2c, 3b and 5b showed significant AhR antagonist activity in a transgenic zebrafish model. Among them, compound 3b, and 5b were found to have excellent AhR antagonist activity with IC50 of 3.36 nM and 8.3 nM in a luciferase reporter gene assay. In stem

  合成了一系列新的1,3-二酮，杂环和α，β-不饱和衍生物，并使用斑马鱼和哺乳动物细胞评估了它们的AhR拮抗剂活性。在转基因斑马鱼模型中，化合物1b，2c，3b和5b显示出显着的AhR拮抗剂活性。其中，在荧光素酶报告基因分析中，发现化合物3b和5b具有出色的AhR拮抗剂活性，IC 50为3.36 nM和8.3 nM。在干细胞增殖测定中，化合物5b引起明显的HSC扩增。
• Radical Trifluoromethoxylation of Arenes Triggered by a Visible‐Light‐Mediated N−O Bond Redox Fragmentation
  作者：Benson J. Jelier、Pascal F. Tripet、Ewa Pietrasiak、Ivan Franzoni、Gunnar Jeschke、Antonio Togni

  DOI：10.1002/anie.201806296

  日期：2018.10.15

  method enables non‐directed functionalization of C−H bonds on a range of substrates, providing access to aryl trifluoromethyl ethers. This light‐driven process is distinctly different from conventional procedures and occurs through an OCF3 radical mechanism mediated by a photoredox catalyst, which triggers an N−O bond fragmentation. The pyridinium‐based trifluoromethoxylation reagent is bench‐stable and

  一种简单的三氟甲氧基化方法可以在一系列底物上实现CH键的非定向功能化，从而可以使用芳基三氟甲基醚。这种光驱过程与传统方法有明显不同，它是通过光氧化还原催化剂介导的OCF 3自由基机理发生的，该机理引发了N-O键断裂。基于吡啶鎓的三氟甲氧基化试剂具有台式稳定性，可通过操作简单的方式获得铅化合物的合成多样性。
• [EN] DIFLUOROMETHOXYLATION AND TRIFLUOROMETHOXYLATION COMPOSITIONS AND METHODS FOR SYNTHESIZING SAME<br/>[FR] COMPOSITIONS DE DIFLUOROMÉTHOXYLATION ET DE TRIFLUOROMÉTHOXYLATION ET LEURS PROCÉDÉS DE SYNTHÈSE
  申请人：UNIV NEW YORK STATE RES FOUND

  公开号：WO2019168874A1

  公开（公告）日：2019-09-06

  The present invention provides a compound having the structure (I), a processing of making the compound; and a process of using the compound as a reagent for the difluoromethoxylation and trifluoromethoxylation of arenes or heteroarenes.

  本发明提供了一种具有结构（I）的化合物，制备该化合物的方法；以及将该化合物用作芳烃或杂环芳烃的二氟甲氧基化和三氟甲氧基化试剂的方法。
• Redox‐Neutral TEMPO Catalysis: Direct Radical (Hetero)Aryl C−H Di‐ and Trifluoromethoxylation
  作者：Johnny W. Lee、Sanghyun Lim、Daniel N. Maienshein、Peng Liu、Ming‐Yu Ngai

  DOI：10.1002/anie.202009490

  日期：2020.11.23

  Applications of TEMPO. catalysis for the development of redox‐neutral transformations are rare. Reported here is the first TEMPO.‐catalyzed, redox‐neutral C−H di‐ and trifluoromethoxylation of (hetero)arenes. The reaction exhibits a broad substrate scope, has high functional‐group tolerance, and can be employed for the late‐stage functionalization of complex druglike molecules. Kinetic measurements

  TEMPO 的应用。氧化还原中性转化发展的催化作用很少见。这里报道的是第一个TEMPO 。（杂）芳烃的催化氧化还原中性 C−H 二氟甲氧基化和三氟甲氧基化。该反应表现出广泛的底物范围，具有较高的官能团耐受性，可用于复杂药物分子的后期功能化。动力学测量、催化中间体的分离和重新研究、UV/Vis 研究和 DFT 计算支持了所提出的氧化 TEMPO 。/TEMPO +氧化还原催化循环。机理研究还表明Li 2 CO 3在防止催化剂失活方面发挥着重要作用。这些发现将为通过氧化还原中性 TEMPO 设计和开发新型反应提供新的见解。催化。
• Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
  申请人：AVENTIS PHARMA S.A.

  公开号：US20040248884A1

  公开（公告）日：2004-12-09

  The present invention relates to a cyclic urea compound of formula I: 1 as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

  本发明涉及一种如下式的环脲化合物： 1 如本文所定义。该发明还涉及其制备方法，包括它的药物组合物以及其作为蛋白激酶抑制剂的药用，因此，它对于预防或治疗能够通过抑制蛋白激酶活性而调节的生理紊乱是有用的，比如固体肿瘤。